StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Adcetris (brentuximab vedotin ADC by Quarter

Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Adcetris (brentuximab vedotin ADC: $196M in Q2 2026, down 23.1% from a year earlier.

Latest, Q2 2026
196
Period ended Jun 28, 2026
Change on a year earlier
-23.1%
255 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| Adcetris (e) | 196 | 255 | (23%) | (23%) | 192 | 248 | (23%) | 4 | 6 | (37%) | (39%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026196-23.1%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026190-12.8%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025220-22.8%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025215-19.8%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025255-8.6%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025218-15.2%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024285+408.9%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024268–Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 2024279–Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024257–Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 202356–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 20230–Form 10-Q (filed 2024-11-04) ↗
Q2 2023Jul 2, 20230–Form 10-Q (filed 2024-08-05) ↗
Q1 2023Apr 2, 20230–Form 10-Q (filed 2024-05-08) ↗

Breakdown

What makes up adcetris (brentuximab vedotin ADC

Cite this data

StockData. (2026). Pfizer Adcetris (brentuximab vedotin ADC ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/adcetris-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.